Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Kailibinuer Abulikemu
Observed name:
kailibinuer Abulikemu
Institution:
People's Hospital of Xinjiang Uygur Autonomous Region
Observed institution:
People's Hospital of Xinjiang Uygur Autonomous Region
ORCID:
0000-0003-4209-3615
Observed ORCID:
0000-0003-4209-3615
OpenAlex ID:
A5024481386
Targeting therapy in pemphigus: Where are we now and where are we going?
2023
·
Kailibinuer Abulikemu
, Fengxia Hu
, et al.
·
Heliyon
·
32
PDF
Safety and Efficacy of Nemolizumab for Patients with Pruritus: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trial
2022
·
Junqin Liang
, Fengxia Hu
, et al.
·
Frontiers in Immunology
·
30
Nine cases of refractory bullous pemphigoid treated with dupilumab and literature review
2023
·
Junqin Liang
, Kailibinuer Abulikemu
, et al.
·
International Immunopharmacology
·
21
Interleukin‐37 inhibits desmoglein‐3 endocytosis and keratinocyte dissociation via upregulation of Caveolin‐1 and inhibition of the STAT3 pathway
2023
·
Junqin Liang
, Fengxia Hu
, et al.
·
Journal of the European Academy of Dermatology and Venereology
·
9
Correction: Safety and efficacy of nemolizumab for patients with pruritus: a systematic review and meta-regression analysis of randomized controlled trial
2026
·
Junqin Liang
, Fengxia Hu
, et al.
·
Frontiers in Immunology
·
1
PDF
ISID0141 - Therapeutic potential of targeting drug in pemphigus
2023
·
kailibinuer Abulikemu
Show more works
View as search
Works count:
6
Citation count:
93
H-index:
4
I10-index:
3
Year
Topic
Type